FDA Approves First Generic Strattera for the Treatment of ADHD
May 30, 2017 -- The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Apotex Inc., Teva Pharmaceuticals...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: ADHD | Food and Drug Administration (FDA) | Hyperactivity | Pediatrics | Pharmaceuticals | Strattera